Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer

作者
Youngkyung Jeon,Sehhoon Park,Se‐Hoon Lee,Tae Hyuk Kim,Sun Wook Kim,Myung‐Ju Ahn,Hyun Ae Jung,Jae Hoon Chung
出处
期刊:Cancer Research and Treatment [Korean Cancer Association]
卷期号:56 (4): 1270-1276 被引量:18
标识
DOI:10.4143/crt.2023.1278
摘要

PURPOSE: BRAF mutations are detected in 30%-80% of papillary thyroid cancer (PTC) cases. DaBRAFenib and trametinib showed promising antitumor activity in patients with BRAFV600E-mutated metastatic melanoma and non-small cell lung cancer. This study aimed to evaluate the efficacy and safety of daBRAFenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer. MATERIALS AND METHODS: This was a retrospective study to evaluate the efficacy of daBRAFenib and trametinib in patients with metastatic BRAFV600E-mutated PTC. The patients received daBRAFenib 150 mg twice daily and trametinib 2 mg once daily at the Samsung Medical Center. This study evaluated the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) overall survival (OS), and safety of daBRAFenib and trametinib. RESULTS: Between December 2019 and January 2022, 27 PTC patients including eight patients with poorly differentiated or anaplastic transformation, received daBRAFenib and trametinib. The median age was 73.0 years, and the median follow-up period was 19.8 months. The majority (81.5%) had undergone thyroidectomy, while 8 patients had received prior systemic treatments. ORR was 73.1%, with 19 partial responses, and DCR was 92.3%. Median PFS was 21.7 months, and median OS was 21.7 months. Treatment-related adverse events included generalized weakness (29.6%), fever (25.9%), and gastrointestinal problems (22.2%). Dose reduction due to adverse events was required in 81.5% of the patients. CONCLUSION: DaBRAFenib and trametinib demonstrated a high ORR with promising PFS; however, most patients with BRAFV600E-mutated metastatic PTC required a dose reduction.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
楚鹏宇发布了新的文献求助10
刚刚
Jack发布了新的文献求助10
刚刚
落后曲奇发布了新的文献求助10
1秒前
1秒前
ding的应助被嗷呜采纳,获得10
2秒前
司念者你完成签到 ,获得积分10
2秒前
2秒前
Young发布了新的文献求助10
2秒前
啊啊啊发布了新的文献求助10
3秒前
3秒前
Owen的应助被乐鱼采纳,获得10
3秒前
3秒前
111完成签到 ,获得积分10
3秒前
4秒前
禽兽琦完成签到,获得积分10
5秒前
hapea完成签到,获得积分10
5秒前
深情安青的应助被大意的凝芙采纳,获得20
5秒前
少年的回忆完成签到,获得积分10
5秒前
香蕉觅云的应助被小小采纳,获得10
6秒前
香蕉君达完成签到,获得积分10
6秒前
研友_8KXdRL完成签到,获得积分10
6秒前
6秒前
8秒前
一芜所有发布了新的文献求助10
8秒前
9秒前
9秒前
222完成签到 ,获得积分10
9秒前
小龚发布了新的文献求助10
9秒前
Lucas的应助被205采纳,获得10
10秒前
10秒前
10秒前
爆米花的应助被科研通管家采纳,获得10
11秒前
11秒前
在水一方的应助被科研通管家采纳,获得10
11秒前
搜集达人的应助被科研通管家采纳,获得10
11秒前
研友_VZG7GZ的应助被少年的回忆采纳,获得10
11秒前
华仔的应助被科研通管家采纳,获得10
11秒前
赘婿的应助被科研通管家采纳,获得10
11秒前
赘婿的应助被科研通管家采纳,获得10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527